KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock News
NASDAQ:KZIA - Nasdaq - US48669G2049 - ADR - Currency: USD
KZIA Latest News, Press Releases and Analysis
What's going on in today's session
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Which stocks are gapping on Friday?
Let's have a look at the gap up and gap down stocks in today's session.
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and...
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has...
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has...
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with the FDA. In July 2024, the company reported topline results from the GBM-AGILE study in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed a clinically meaningful improvement in a prespecified secondary analysis for overall survival (OS) compared to standard
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
Kazia Therapeutics updates paxalisib's regulatory progress after FDA discussions on glioblastoma data, highlighting plans for a pivotal Phase 3 trial.
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for...
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration...
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
/PRNewswire/ -- With every October, breast cancer awareness surges thanks to very effective campaigns and new developments in breast cancer treatment. However,...
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I...
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data...
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been...
7 Top Stocks Under $10: July 2024 Edition
There are more than 2,100 stocks under $10 from which to choose in the market. If you want to find the best, use the Portfolio Grader.
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics
Kazia Therapeutics stock is a fast mover in both directions and has long-term rally potential after Kazia Therapeutics' clinical victory.
From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher
If you’ve read all the warnings and still want to jump into some of the top penny stocks to buy, focus on the key fundamentals.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Silk Recalls 2024: What to Know as Plant-Based Milk Recalled Over Listeria Concerns
Silk recalls are a hot topic on Thursday as the plant-based milk alternative is being pulled from shelves due to listeria concerns.
FCEL Stock Alert: FuelCell Energy Pops on Korean Market Update
FuelCell Energy stock is up on Thursday as FCEL investors are excited about the company's Korean presentation and expansion news.
JOBY Stock Pops After Completing 523-Mile eVTOL Flight
Joby Aviation stock is flying higher on Thursday after the eVTOL company reported a new milestone for a hydrogen-electric aircraft.
KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains
Kazia Therapeutics stock is still rallying on Thursday with heavy trading of KZIA alongside its latest positive clinical trial data.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news affecting shares this morning!